The Senate Health, Education, Labor and Pensions Committee today held the second in a series of hearings examining the 340B drug savings program.
At the hearing, representatives from the Department of Health and Human Services Office of Inspector General and Government Accountability Office testified on oversight reports related to the program and shared recommendations for improving it.
Ann Maxwell, OIG’s assistant inspector general for evaluation and inspections, said the Health Resources and Services Administration, which oversees the 340B program, has made “great strides in improving program integrity,” but more must be done related to transparency and program rules.
HELP Committee Chairman Lamar Alexander (R-TN) said he hears often that hospitals and clinics are using the 340B program to benefit low-income patients, but questions whether “HRSA’s lack of oversight authority has made it difficult for us to have agreement on a common set of data about the 340B program so that we can make such determinations.”  
HELP Committee Ranking Member Patty Murray (D-WA) described how a number of hospitals in her state are using the 340B program to fund a variety of programs that increase access to care for patients in vulnerable communities. Murray said that the 340B program should be strengthened and there should be “more accountability and transparency for everyone in our drug system.”
During the hearing, Murray and a number of senators spoke about repeated delays in implementing a final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. The rulemaking on this issue began seven years ago, and last week HRSA proposed delaying the effective date to July 1, 2019.
“No one should be above the law and that includes giant drug companies that are raking in profits while complaining about a program that helps out our most vulnerable patients,” said Sen. Elizabeth Warren (D-MA).
Sen. Susan Collins (R-ME) spoke about the importance of the 340B program in Maine. She cited data from the Maine Hospital Association that showed 25 hospitals in the state participated in the 340B program, 14 of those hospitals already have negative operating margins, and a number of others would have negative margins if not for the 340B program.

In a statement submitted for the hearing, AHA said that for more than 25 years “the 340B program has been critical in helping hospitals expand access to lifesaving prescription drugs and comprehensive health care services in vulnerable communities across the country, including to low-income and uninsured individuals ... AHA and its member hospitals and health systems support program integrity efforts to ensure that the 340B program meets the objective set by Congress” and “we continue to work with HRSA and its partners on these efforts.”

Related News Articles

About 34 percent of uninsured U.S. adults did not take their medication as prescribed in 2017 in order to reduce their prescription drug costs, according to a…
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive…
The Centers for Medicare & Medicaid Services today updated its Medicare and Medicaid drug spending dashboards with 2017 data.
The House Energy and Commerce Health Subcommittee today held a hearing to discuss seven bills aimed at increasing competition in the prescription drug market…
The Senate Special Committee on Aging today concluded a two-part hearing on the impact of rising prescription drug costs on seniors and potential policy…
Eight in 10 U.S. adults say prescription drug costs are “unreasonable,” and one in four say their prescription medicines are difficult to afford, according to…